By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novartis Oncology 

East Hanover  New Jersey    U.S.A.
Phone: 888-NOW-NOVA Fax:




Company News
Health Canada Approves Novartis Oncology (NVS)'s AFINITOR for Breast Cancer 1/16/2013 7:36:34 AM
ASA404 to Feature in Novartis Oncology (NVS) Pipeline Update and at San Antonio Breast Cancer Symposium 12/9/2009 10:30:49 AM
Newly Published Phase III Data Show Novartis Oncology (NVS) (JOBS) Drug Sandostatin(R) LAR Depot Reduced Risk of Disease Progression by 66% in Advanced NET Patients 10/1/2009 6:40:31 AM
Novartis Oncology (NVS): Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy(1, 2) 9/25/2009 11:07:39 AM
Novartis Oncology (NVS)'s Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5/8/2009 11:55:46 AM
Novartis Oncology (NVS) Release: Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women 4/30/2007 1:50:04 PM
NICE Initial Recommendation: One Step Closer To Backing Aromatase Inhibitor Treatment For Women With Early Breast Cancer 5/23/2006 11:25:33 AM
Novartis Oncology (NVS) Release: Femara Endorsed Post-Surgery For Women With Early Breast Cancer In Scotland...But Women In The Rest Of The UK Must Wait A Further 6 Months 5/8/2006 1:15:03 PM
Novartis Oncology (NVS) Release: New Clinical Data Show Dramatic Benefits Of Femara(R) For Women With Breast Cancer Even After Prolonged Period Of No Anti-Cancer Treatment 12/13/2005 12:22:24 PM
Novartis Oncology (NVS) Release: UK Leads Europe And US In Milestone Post-op Breast Cancer Treatment Decision 12/8/2005 11:06:48 AM